Program
DA-302168S
A development code. Also written as “[14C] DA-302168S” and “15 mg DA-302168S tablet”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by Chendu DIAO Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chendu DIAO Pharmaceutical Group | 95 open or running | phase 3since May 27, 2026 | Jul 26, 2024 | Dec 12, 2026phase 1 · NCT07938515 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 26, 2024First studies: 2 phase 1 studies in OverweightFirst studyNCT06534346, NCT06534320
- Aug 1, 2024Phase 1 study in OverweightNCT06541730 · 48 enrolled · China
- Apr 11, 2025Phase 2 study in OverweightNCT06953063 · 250 enrolled · China
- May 27, 2026Phase 3 study in OverweightPhase 3 reachedNCT07629544 · 840 planned · China
- Aug 5, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07755150 · 272 planned · China
- Sep 29, 2026Phase 1 study in Healthy Adult SubjectsNCT07857265 · 10 planned
- Oct 9, 2026Phase 1 study in ObesityNCT07877038 · 32 planned
- Nov 10, 2026Phase 1 study in ObesityNCT07938515 · 32 planned · China
Ahead
- Dec 12, 2026Primary completion: phase 1 study in ObesityNCT07938515
- Dec 20, 2026Primary completion: phase 1 study in Healthy Adult SubjectsNCT07857265
- Apr 7, 2027Primary completion: phase 1 study in ObesityNCT07877038
- Jul 9, 2027Primary completion: phase 3 study in OverweightNCT07629544
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07938515Obesity · China | 1 | Recruiting | Dec 12, 2026 | 32 |
| NCT07877038Obesity | 1 | Not yet recruiting | Apr 7, 2027 | 32 |
| NCT07857265Healthy Adult Subjects | 1 | Not yet recruiting | Dec 20, 2026 | 10 |
| NCT07755150Diabetes Mellitus, Type 2 · China | 2 | Not yet recruiting | Oct 20, 2027 | 272 |
| NCT07629544Overweight · China | 3 | Recruiting | Jul 9, 2027 | 840 |
| NCT06953063Overweight · China | 2 | Completed | Dec 15, 2025 | 250 |
| NCT06541730Overweight · China | 1 | Completed | Jan 30, 2025 | 48 |
| NCT06534346Overweight · China | 1 | Completed | Aug 3, 2024 | 16 |
| NCT06534320Overweight · China | 1 | Completed | Dec 31, 2024 | 50 |
How it is read
Names in the registry
- “DA-302168S”, 9 entries
- “[14C] DA-302168S”, 1 entry
- “15 mg DA-302168S tablet”, 1 entry
Codes read as this program: DA302168S.
Conditions, from the studies’ own filings
- Obesity, 7 studies
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.